Obesity is a major public health concern in the United States and has been linked to many health problems such as heart disease, stroke, diabetes, high blood pressure, sleep disorders, and breathing problems. According to 2015 estimates by the American Society for Metabolic and Bariatric Surgery (ASMBS), roughly 19 million US adults qualified as morbidly obese, and only estimated 196,000 bariatric surgeries were performed, including laparoscopic sleeve gastrectomies, gastric bypass surgeries, and laparoscopic adjustable bands. Treatments for obesity range from healthy eating and exercise, to prescription medicine and surgery. FDA-regulated medical devices also help treat obesity. Currently, there are four types of FDA-approved devices on the market designed to treat obesity: gastric band – bands are placed around the top portion of the stomach leaving only a small portion available for food (lap-band, realize band – Swedish adjustable gastric band), gastric balloon systems – inflatable balloons are placed in the stomach to take up space (ReShape Duo – integrated dual balloon system, Orbera intragastric balloon system, Obalon balloon system), gastric electrical stimulation systems – electrical stimulator is placed in the abdomen to block nerve activity between the brain and stomach (vBloc therapy systems, maestro rechargeable system), gastric emptying systems or aspiration systems – a tube is inserted between the stomach and outside of abdomen to drain food after eating (AspireAssist).
The global obesity treatment devices market segmentation is based on device type (gastric banding systems, gastric balloon systems, gastric electrical stimulation systems, gastric emptying systems or gastric aspiration systems, other emerging devices – endoluminal bypass liners, oral appliances); and surgery procedure (Roux-en-Y gastric bypass surgery, adjustable gastric band, laparoscopic sleeve gastrectomy, biliopancreatic diversion with duodenal switch, revisions, other surgical procedures).
The global obesity treatment devices market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global obesity treatment devices market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global obesity treatment devices market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global obesity treatment devices market and profiled in this report include Allergan, Inc., Apollo Endosurgery, Inc., Aspire Medical, Inc. (Aspire Bariatrics), Boston Scientific Corp., Cousin Biotech, CR Bard, Inc., EnteroMedics, Inc., GI Dynamics, Inc., GI Windows, Inc., Johnson & Johnson, Leptos Biomedical, Mediflex Surgical Products, Medtronic, Inc., ReShape Medical, Inc., Satiety, Inc., Spatz FGIA, Inc., and TransEnterix, Inc.